Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latin American Countries Easing Strict Rules on Product Retesting

This article was originally published in PharmAsia News

Executive Summary

Latin American regulators are easing strict local testing requirements for pharmaceuticals, offering a glimmer of hope for multinational companies that are continuously challenged by the time and cost involved in conducting duplicate testing.

You may also be interested in...



US FDA Allows Outsourcers To Compound Hydroxychloroquine As COVID-19 Drives Demand

The US FDA has added hydroxychloroquine sulfate to the list of drugs outsourcing facilities can compound as pharmacy group calls for more such approvals with COVID-19 driving demand for additional prescription and over-the-counter drugs.

In Pandemic Response, Quality Experts Advise Drug Manufacturers Move Products To Local Sites

AstraZeneca emptied its warehouses in January. “We said, OK let us pack everything and get it out in the door,” said Tony Mire-Sluis, head of global quality. The firm is allowing only crucial personnel in plants, or those responsible for running a plant or moving products; all others are working from home.

Quality Experts Advise Industry To Move Products To Local Sites In Responding To COVID-19

Quality experts with AstraZeneca and Thermo Fisher describe how their companies are responding to the COVID-19 pandemic – but urge industry not to lose focus on monitoring unrelated drug products.

Topics

UsernamePublicRestriction

Register

SC087074

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel